Donna Armentano received a Bachelor of Arts degree from Cornell University where she studied Biochemistry and Molecular Biology. She received her Ph.D. from Princeton University where she studied retroviral vectors and their application to treating adenosine deaminase deficiency (SCID-ADA). Her post-doctorate research at Baylor College of Medicine focused on treatment of hemophilia B and PKU using retroviral vector delivery to liver cells. Before joining Pfizer, she was employed at Genzyme for 24 years. During her tenure she worked on developing a variety of gene delivery vectors (adenoviral, lentiviral and AAV) for gene therapy applications spanning a broad array of therapeutic areas (CF, diabetes, Lysosomal Storage Diseases, AD, hemophilia A). She also worked on developing manufacturing strategies for lentiviruses and AAV. Donna is currently Executive Director, Global Head of Gene Therapy for Pfizer’s External R&D Innovation team. Her role includes evaluation of opportunities and novel technologies to build Pfizer’s Gene Therapy pipeline.